Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wattana Karnpaet PCLBKK:NEW 81 3-Year EBITDA Growth Rate is -15.50% as of Jun. 2026. GuruFocus rates BKK:NEW with a GF Score™ of 81/100 and a GF Value™ of ฿98.34 (Fairly Valued). The stock has 2 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Wattana Karnpaet PCL ranks worse than 85.74% on this metric.
During the past 12 months, Wattana Karnpaet PCL's average EBITDA Per Share Growth Rate was 3.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -15.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Wattana Karnpaet PCL was 45.50% per year. The lowest was -22.40% per year. And the median was 7.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Wattana Karnpaet PCL 3-Year EBITDA Growth Rate Related Terms
BKK:NEW vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Wattana Karnpaet PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wattana Karnpaet PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Wattana Karnpaet PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Wattana Karnpaet PCL's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -15.50% mean?
Wattana Karnpaet PCL (BKK:NEW) has a 3-Year EBITDA Growth Rate of -15.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Wattana Karnpaet PCL and its competitors. According to the industry distribution chart, Wattana Karnpaet PCL ranks #451 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 85.7%.
Is Wattana Karnpaet PCL's 3-Year EBITDA Growth Rate too high?
Wattana Karnpaet PCL's current 3-Year EBITDA Growth Rate is -15.50%. Based on the distribution chart, Wattana Karnpaet PCL ranks #451 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Wattana Karnpaet PCL has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wattana Karnpaet PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Wattana Karnpaet PCL ranks #451 out of 526 companies for 3-Year EBITDA Growth Rate. This places Wattana Karnpaet PCL in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Wattana Karnpaet PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wattana Karnpaet PCL's current 3-Year EBITDA Growth Rate is -15.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wattana Karnpaet PCL stock overvalued right now?
Based on GuruFocus' analysis, Wattana Karnpaet PCL (BKK:NEW) is currently considered Fairly Valued. The stock's GF Value™ is ฿98.34, compared to a current price of ฿92.75 — trading 5.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -15.50%. Wattana Karnpaet PCL's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Wattana Karnpaet PCL (BKK:NEW), the current 3-Year EBITDA Growth Rate is -15.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wattana Karnpaet PCL (BKK:NEW) Overvalued in 2026?
Based on GuruFocus' analysis, Wattana Karnpaet PCL stock appears to be undervalued.
The current stock price of ฿92.75 is trading 5.7% below its estimated GF Value™ of ฿98.34.
GuruFocus considers Wattana Karnpaet PCL to be Fairly Valued.
Key valuation signals for BKK:NEW:
3-Year EBITDA Growth Rate: -15.50%
GF Value™: ฿98.34 vs. price of ฿92.75 (5.7% below fair value)
No single metric tells the full story. See the BKK:NEW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wattana Karnpaet PCL is engaged in the operation of a hospital under the name North Eastern Wattana Hospital. It has a single segment of operation, namely the hospital and medical trading business. The company earns revenue from hospital, revenue from sales of medicines, and revenue from hospital rooms, which are derived from the provision of services to various types and a large number of customers. Geographically, the company's operations are carried out in Thailand.
81GF Score
Get the complete analysis for BKK:NEW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NEW has been successfully added to your 
